# EDGAR Filing Document

**Accession Number:** 0001975641
**File Stem:** 0001213900-26-019331
**Filing Date:** 2026-2
**Character Count:** 3171
**Document Hash:** 7ff091e2716f81837e88426a3455a080
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-019331.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001213900-26-019331

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260223

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zhengye Biotechnology Holding Ltd
- **CENTRAL INDEX KEY:** 0001975641
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F4

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42450
- **FILM NUMBER:** 26665245

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO.1 LIANMENG STREET, JILIN ECONOMIC &
- **STREET 2:** TECHNICAL DEVELOPMENT ZONE
- **CITY:** JILIN
- **PROVINCE COUNTRY:** F4
- **BUSINESS PHONE:** 86-13844801919

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO.1 LIANMENG STREET, JILIN ECONOMIC &
- **STREET 2:** TECHNICAL DEVELOPMENT ZONE
- **CITY:** JILIN
- **PROVINCE COUNTRY:** F4

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**Commission File Number: 001-42450**

**Zhengye Biotechnology Holding Limited**

**No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone<br> Jilin City, Jilin Province, China**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Resignation of Independent Director**

On February 18, 2026, Mr. Wenbin Wang, an independent director of Zhengye Biotechnology Holding Limited (the "Company"), resigned from the board of directors (the "Board") and each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Compensation Committee of the Board, effective February 18, 2026. Mr. Wang's resignation from the Board and the three committees was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Mr. Wang acknowledges that he has been paid all amounts due to him and is not entitled to any payments or benefits of any kind from the Company, and irrevocably and unconditionally releases the Company of and from all claims, demands, actions, and causes of actions.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Zhengye Biotechnology Holding Limited** | **Zhengye Biotechnology Holding Limited** |
| Date: February 23, 2026 | By: | */s/ Songlin Song* |
|  | Name: | Songlin Song |
|  | Title: | Chief Executive Officer |

---